Loosing Januvia scripts to EVERYONE!

Quote

Anonymous

Guest
Why is my share and script volume dropping every time I look at the reports.

It’s starting to piss me off, everyone else is growing except Avandia and Januvia.

I feel like I have to beg doctors to write and they don't. All I hear is, do you have weight loss? Are you on Formulary? How much is your co-pay? Are you better then Onglyza, Victoza, and we have NO FREAKIN DATA to answer any of this crap.

GOD we need some new drugs.
 






Anonymous said:
Why is my share and script volume dropping every time I look at the reports.

It’s starting to piss me off, everyone else is growing except Avandia and Januvia.

I feel like I have to beg doctors to write and they don't. All I hear is, do you have weight loss? Are you on Formulary? How much is your co-pay? Are you better then Onglyza, Victoza, and we have NO FREAKIN DATA to answer any of this crap.

GOD we need some new drugs.
Click to expand...

If you are getting beat by Onglyza and Victoza you need to go find another job...seriously
 






Anonymous said:
Why is my share and script volume dropping every time I look at the reports.

It’s starting to piss me off, everyone else is growing except Avandia and Januvia.

I feel like I have to beg doctors to write and they don't. All I hear is, do you have weight loss? Are you on Formulary? How much is your co-pay? Are you better then Onglyza, Victoza, and we have NO FREAKIN DATA to answer any of this crap.

GOD we need some new drugs.
Click to expand...

Don't hold your breathe for any new drugs.
 












well you had to know that the dpp-4 window was narrow and is now closing fast. soon it will be like arb's and statins - every company will have one. then the micro increases will go to the best marketers (diovan) most agressive w/mco's (benicar) or most effective (lipitor). Which is all to say - history is not in merck's corner.
 






The latest issue of Consumers Report recommends metformin and a sulfonylurea for cost and effectiveness over Januvia, which it said is expensive and may cause hypoglycemia. Guess who would read the article? Ask yourself when you can pay $8 totally for a month worth of these two products, with the poor economy right now, would you opt for Januvia?
 






Januvia sucks. its expensive as hell, barely works, has worsening MHC coverage and is getting its butt kicked on NRX by everyone else. if it wasnt for refills we would all be fired by now.

and its going to get worse.
The only way I can get a script these days is to load the doctor up with samples and tell him/her to give the patient a 3 month supply of samples to try it out.

I second the request to get us some more drugs, and fast! but I know better then most this isn't going to happen anytime soon.
 












that's what happens when you sell in a saturated market. some docs prefer their own prescribing habits, some are influenced by reach and frequency, but most go by results/costs.

If januvia sucks, then you may just have to become buddies with your top docs and pretend to like them while doing it all for job security.
 






"We don't just test drugs the way we test cars...we use research from experts at the Drug Effectiveness Review Project,,,based in Oregon.
Free Report:www.ConsumerReports Health.org/BestBuyDrugs covers 25 classes of drugs for more than 35 conditions.They show the consumer $100/drug/mos savings.
Generic is the road to savings.
Do you think Merck in these uncertain moments of the future is going to take all of their monies and invest in new drugs?....hell, no!! You better keep some cash for the lawsuits and the TAXES from Oblabla's presidency. Can hardly wait until the big O is gone--2012 election can not come soon enough!!
 






Anonymous said:
"We don't just test drugs the way we test cars...we use research from experts at the Drug Effectiveness Review Project,,,based in Oregon.
Free Report:www.ConsumerReports Health.org/BestBuyDrugs covers 25 classes of drugs for more than 35 conditions.They show the consumer $100/drug/mos savings.
Generic is the road to savings.
Do you think Merck in these uncertain moments of the future is going to take all of their monies and invest in new drugs?....hell, no!! You better keep some cash for the lawsuits and the TAXES from Oblabla's presidency. Can hardly wait until the big O is gone--2012 election can not come soon enough!!
Click to expand...

Actually, Frazier is making research a priority, unlike Pfizer. But Merck's R&D reputation isn't good. You can pour all the money in the world into it, but it may be for nothing.
 






Anonymous said:
"We don't just test drugs the way we test cars...we use research from experts at the Drug Effectiveness Review Project,,,based in Oregon.
Free Report:www.ConsumerReports Health.org/BestBuyDrugs covers 25 classes of drugs for more than 35 conditions.They show the consumer $100/drug/mos savings.
Generic is the road to savings.
Do you think Merck in these uncertain moments of the future is going to take all of their monies and invest in new drugs?....hell, no!! You better keep some cash for the lawsuits and the TAXES from Oblabla's presidency. Can hardly wait until the big O is gone--2012 election can not come soon enough!!
Click to expand...

Don't bet on O leaving any time soon. A few R states in the South are leaning away from the GOP- could be a very interesting 2012 especially if the H o R turn out to be all fluff and no substance
 






Anonymous said:
Januvia sucks. its expensive as hell, barely works, has worsening MHC coverage and is getting its butt kicked on NRX by everyone else. if it wasnt for refills we would all be fired by now.

and its going to get worse.
The only way I can get a script these days is to load the doctor up with samples and tell him/her to give the patient a 3 month supply of samples to try it out.

I second the request to get us some more drugs, and fast! but I know better then most this isn't going to happen anytime soon.
Click to expand...

Troll
 






Anonymous said:
Don't bet on O leaving any time soon. A few R states in the South are leaning away from the GOP- could be a very interesting 2012 especially if the H o R turn out to be all fluff and no substance
Click to expand...

O being forced to the center with last election conservative wake-up call. It shocked him to change and move away from his extreme. If stays in the "center" there he could get in again.
 






Doctors and other drug companies used to bow down and worship at the mention of MSDRL (Merck Sharp & Dohme Research Lab). What have we done to be mocked and laughed at these days?
 






Anonymous said:
Actually, Frazier is making research a priority, unlike Pfizer. But Merck's R&D reputation isn't good. You can pour all the money in the world into it, but it may be for nothing.
Click to expand...

....isn't that P.Kim has done for the last gaaa zillion years....pour money into nothing???
That is why the sales force is shrinking!!!!! and keeps on shrinking and shrinking.
 












Well if you think times are tough for Januiva having to compete against generic SU's, one other DPP-IV (saxa) and the GLP-1's (Byetta and Victoza), just wait until the SGLT-2's come charging out of the gate in the next 2 years. Do some reading on canagliflozin and dapagliflozin (both in Ph 3 with J&J and BMS, respectively). BI has an SGLT-2 in development too.

All are once-daily tablets that can generate a similar A1c reduction to GLP-1's and 8-10 lb. weight loss like a GLP-1, but without the needle...... Rates of AE's like UTI's vary amongst the three, but one of them is sure to have the acceptable safety/efficacy balance to be a hit. They can also can be insulin-sparing for T1DM patients or more-advanced T2DM patients on insulin, which means they can play in both T1/T2 markets and can be used early/late in the disease progession for T2.

With the expiry of glargine's patent in 2013, hang onto your hats, it's going to be shake-up time for the established players (both tsblet and injectables) in the diabetes marketplace....
 






Fast acting insulin sales up across the board at Novo, Lilly and Sanofi as way more type IIs taking bolus insulin and docs treating aggressively. All these oral do is give the patient the poops.

Anonymous said:
Well if you think times are tough for Januiva having to compete against generic SU's, one other DPP-IV (saxa) and the GLP-1's (Byetta and Victoza), just wait until the SGLT-2's come charging out of the gate in the next 2 years. Do some reading on canagliflozin and dapagliflozin (both in Ph 3 with J&J and BMS, respectively). BI has an SGLT-2 in development too.

All are once-daily tablets that can generate a similar A1c reduction to GLP-1's and 8-10 lb. weight loss like a GLP-1, but without the needle...... Rates of AE's like UTI's vary amongst the three, but one of them is sure to have the acceptable safety/efficacy balance to be a hit. They can also can be insulin-sparing for T1DM patients or more-advanced T2DM patients on insulin, which means they can play in both T1/T2 markets and can be used early/late in the disease progession for T2.

With the expiry of glargine's patent in 2013, hang onto your hats, it's going to be shake-up time for the established players (both tsblet and injectables) in the diabetes marketplace....
Click to expand...
 












Top Bottom
Back
Quote